Drug Profile
Amlitelimab - Kymab/Sanofi
Alternative Names: KY-1005; SAR-445229Latest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Kymab
- Developer Kymab; Sanofi
- Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Immunomodulators; OX40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Atopic dermatitis
- Phase II Asthma; Autoimmune disorders; Hidradenitis suppurativa
- No development reported Graft-versus-host disease